Shilpa Medicare · NSE: SHILPAMED · BSE: 530549

Q3 FY26 results · Oct–Dec 2025

Shilpa Medicare reported revenue from operations of ₹409.73 crore (up 28.3% from Q3 FY25) and net profit of ₹44.58 crore (up 40.3% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
ItemQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue from operations409.73319.32+28.3%369.97+10.7%
Other income0.811.13−28.1%1.75−53.6%
Total income410.54320.45+28.1%371.72+10.4%
Profit before share of associates & JVs and tax61.2141.27+48.3%64.54−5.2%
Share of profit/(loss) of associates & JVs(0.35)0.34(0.11)
Net profit for the period44.5831.78+40.3%44.07+1.2%
EPS, basic (₹)2.363.25not comparable2.25not comparable
Net margin (%)10.910.011.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue from operations165.70125.39+32.2%134.93+22.8%
Other income11.2916.83−32.9%16.94−33.4%
Total income176.99142.21+24.5%151.88+16.5%
Profit before tax23.7925.33−6.1%38.92−38.9%
Net profit for the period15.9316.12−1.2%30.83−48.3%
EPS, basic (₹)0.841.65not comparable1.58not comparable
Net margin (%)9.612.922.8
Consolidated
Filed with BSE
06 Feb 2026, 16:06 IST
Board meeting
06 Feb 2026
Period
01 Oct 2025 to 31 Dec 2025
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
06 Feb 2026, 16:06 IST
Board meeting
06 Feb 2026
Period
01 Oct 2025 to 31 Dec 2025
Review status
Unaudited
Source
XBRL filing on BSE